The value of circulating tumor DNA monitoring in the management of the endocrine therapy of fluvistam in estrogen receptor positive breast cancer patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033307

Enrollment

Unknown

Registered

2020-05-27

Start date

2020-05-20

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Estrogen receptor positive breast cancer

Interventions

case series:Fulvestrant

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who voluntarily participated in the trial and signed the informed consent; 2. Patients aged 18-75 (including border), female; 3. Patients with locally advanced or metastatic postmenopausal breast cancer confirmed by pathology; 4. Patients with ECoG score of 0-2; 5. HR positive patients were detected by IHC, HER2 was not amplified; 6. The patients who want to receive the endocrine therapy of fluvastatin; 7. Patients with sufficient organ and bone marrow functions (results within 14 days before screening are acceptable) are defined as follows: bone marrow: platelets >= 90 x 10 ^ 9 / L, hemoglobin >= 90g / L, leukocytes >= 3.0 x 10 ^ 9 / L, neutrophils >= 1.5 x 10 ^ 9 / L; liver: total bilirubin = 28g / L; kidney: serum creatinine = 50ml / min; other important organs without severe organic diseases; 8. Patients with expected survival time > 6 months.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with clinically diagnosed other malignant tumors; 3. Patients with skin, musculoskeletal, heart, cardio cerebrovascular, blood system, liver, kidney, digestive tract, immune system, endocrine system, nervous system, respiratory system, mental and metabolic diseases, who are not suitable for the study; 4. Patients with uncontrolled active infection (such as active hepatitis, HIV, syphilis and other infections requiring systemic treatment); 5. Subjects with research conflict diseases: mental illness or drug abuse, etc; 6. Patients who apply other anti-tumor measures before and at the same time of the trial or who plan to participate in other clinical trials; 7. Subjects may not be able to complete the study for other reasons, or the researchers think it should not be included.

Design outcomes

Primary

Measure	Time frame
ctDNA;Mutation feature of tissue;Progress-free survival;	—

Countries

China

Contacts

Public ContactWeiqi Nian

Cancer Hospital Affiliated to Chongqing University

nwqone@126.com+ 86 13883652913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026